[go: up one dir, main page]

EP3952670A1 - Composition de poudre hautement disponible contenant du riz rouge - Google Patents

Composition de poudre hautement disponible contenant du riz rouge

Info

Publication number
EP3952670A1
EP3952670A1 EP19727488.9A EP19727488A EP3952670A1 EP 3952670 A1 EP3952670 A1 EP 3952670A1 EP 19727488 A EP19727488 A EP 19727488A EP 3952670 A1 EP3952670 A1 EP 3952670A1
Authority
EP
European Patent Office
Prior art keywords
powder composition
composition according
powder
weight
monacolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19727488.9A
Other languages
German (de)
English (en)
Inventor
Mauro Rissa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmanutrition R and D SRL
Original Assignee
Pharmanutrition R and D SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmanutrition R and D SRL filed Critical Pharmanutrition R and D SRL
Publication of EP3952670A1 publication Critical patent/EP3952670A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/14—Yeasts or derivatives thereof
    • A23L33/145—Extracts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
    • A23L31/10—Yeasts or derivatives thereof
    • A23L31/15—Extracts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
    • A23L7/107—Addition or treatment with enzymes not combined with fermentation with microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention comprises powder compositions containing fermented red yeast rice, a method for preparing said powder compositions and related oral formulations, in the form of a food supplement, of food for special medical purposes and as a cholesterol-lowering medicinal product for use in the prevention and/or the treatment of cardiovascular disorders.
  • Hypercholesterolemia has now been definitely identified as a determining factor in the perspective of an increased cardiovascular risk. This evidence is the result of a long series of epidemiological studies that have clearly correlated cholesterolaemia (plasma cholesterol concentrations) and cardiovascular ischemic events, with specific reference to myocardial infarction and to the relative cardiovascular mortality, of which myocardial infarction and cerebral stroke represent the most frequent aetiology.
  • RYR extracts titrated in Monacolin now represent a solid certainty in adjuvant nutraceutical treatment in patients with mild to moderate cardiovascular risk, not yet candidates for drug therapy with statins and other cholesterol-lowering drugs such as fibrates and ezetimibe.
  • Object of the present invention are therefore powder compositions containing Monascus Purpureus variously titrated in Monacolin K and at least one hydrophilic surfactant agent, preferably at least two hydrophilic surfactants and at least one mucolytic agent.
  • a further object of the present invention are oral formulations, in particular in the form of food supplements, foods for special medical purposes having cholesterol lowering activity for use in the prevention and treatment of cardiovascular disorders.
  • Figure 1 is a photo of a beaker containing the simulated enteric liquid (SIF), whose label shows the different components of said SIF.
  • Figure 2 is a picture of two beakers: the one on the left contains the powder compositions of the present invention completely dissolved in the SIF, which is compared to the one on the right that contains the pure extract of Monascus Purpureus with the same titration in Monacolin K and in the same amounts as the one of the left beaker, although this extract is not completely dissolved in the SIF.
  • SIF enteric liquid
  • the definitions "comprising” and “containing” referring to the powder composition according to the present invention mean that said composition can contemplate the presence of further components in addition to those explicitly reported and described.
  • the at least one surfactant agent is preferably selected from polyoxyethylenated sorbitan esters (polysorbates), sucrose esters with fatty acids (sucroesters), alkyl ethers of glucose (alkyl glucosides).
  • the powder composition of the present invention comprises two hydrophilic surfactants, of which at least one is a polyoxyethylenated sorbitan ester, more preferably selected from polysorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80, and even more preferably is polysorbate 80.
  • two hydrophilic surfactants of which at least one is a polyoxyethylenated sorbitan ester, more preferably selected from polysorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80, and even more preferably is polysorbate 80.
  • the mucolytic agents are preferably selected from N-acetylcysteine, carboxycysteine and their mixture, since they are able to increase the hydro-dispersion of the extract in the intestine and its epithelial permeability.
  • the powder compositions according to the present invention contain only the N-acetylcysteine as the mucolytic agent. From the tests conducted with RYR extracts variously titrated in Monacolin (1, 3 and 5%), the dissolution process in the simulated enteric liquid (SIF) (Fig.
  • Another characteristic of the present invention is the possibility to vehiculate together with the RYR the coenzyme Q10 (inhibition of the HMG-CoA reductase enzyme, involved in the synthesis of mevalonate, a biochemical intermediate necessary for the synthesis of cholesterol as well as of coenzyme Q10) in a highly bioavailable form, notwithstanding the known poor bioavailability of the substance per oral route [8, 9], and exploiting the same mechanisms of increase of enteric hydro-dispersion of the molecule.
  • Chronic statin intake is notoriously associated with adverse muscular effects such as dystrophy, even severe pain (myalgia) and in severe cases rhabdomyo lysis [10, 11].
  • Red yeast rice (RYR) or Monascus Purpureus preferably has a titration in Monacolin K variable between 1 and 20% weight/weight of the RYR.
  • the red yeast rice is contained in amounts comprised between 30 and 70% by weight, more preferably between 40 and 60% by weight on the total weight of the powder composition.
  • the hydrophilic surfactants are contained in a total amount preferably comprised between 10 and 50% by weight, preferably between 20 and 40% by weight on the total weight of the powder composition object of the present invention.
  • the mucolytic agents are preferably contained in amounts comprised between 5 and 25% by weight, more preferably between 10 and 20% by weight on the total weight of the powder composition.
  • the powder composition also contains the coenzyme Q10, this is present in Monascus Purpureus /coenzyme Q10 weight ratios preferably comprised between 1:3 and 1:0.5.
  • the object of the present invention is also the preparation method of the powder composition according to the present invention, which comprises the following steps:
  • step b) moistening the mixture obtained in step a) with water or an aqueous solution of the polyoxyethylenated sorbitan ester, when this hydrophilic humectant is present, and obtaining a granulate,
  • step b) drying the granulate obtained in step b) until a powder is obtained
  • the oral formulations object of the present invention are preferably in the form of water-dispersible tablets, capsules or granulates administrable per oral route.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne : A) une composition de poudre comprenant : • Monascus Purpureus titré en monacoline K, • éventuellement associée à la coenzyme Q10, • au moins un tensioactif hydrophile, et • au moins un agent mucolytique; B) un procédé de préparation desdites compositions de poudre A), et C) des formulations orales contenant les compositions de poudre A) susmentionnées sous la forme de compléments alimentaires, d'aliments à des fins médicales spéciales ou de produits médicinaux abaissant le taux de cholestérol destinés à être utilisés dans le traitement de troubles cardiovasculaires.
EP19727488.9A 2019-04-11 2019-04-11 Composition de poudre hautement disponible contenant du riz rouge Pending EP3952670A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2019/052998 WO2020208404A1 (fr) 2019-04-11 2019-04-11 Composition de poudre hautement disponible contenant du riz rouge

Publications (1)

Publication Number Publication Date
EP3952670A1 true EP3952670A1 (fr) 2022-02-16

Family

ID=66676842

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19727488.9A Pending EP3952670A1 (fr) 2019-04-11 2019-04-11 Composition de poudre hautement disponible contenant du riz rouge

Country Status (2)

Country Link
EP (1) EP3952670A1 (fr)
WO (1) WO2020208404A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202200003191A1 (it) * 2022-02-21 2023-08-21 Inpha Res S R L Composizione per il controllo delle iperlipidemie
IT202200003224A1 (it) * 2022-03-01 2023-09-01 Neilos S R L “Composizione nutraceutica o farmaceutica comprendente un estratto di riso rosso fermentato”

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815310B2 (en) * 2011-01-10 2014-08-26 Morteza Naghavi Compositions for boosting metabolism, assisting weight loss, and promoting cardiovascular health
ITMI20120847A1 (it) * 2012-05-16 2013-11-17 Labomar S R L Formulazione per sostanze a bassa biodisponibilità.
LT3169322T (lt) * 2014-07-18 2020-12-10 Berlin-Chemie Aktiengesellschaft Dietinė kompozicija su atidislipideminiu aktyvumu
AU2015294618A1 (en) * 2014-07-25 2017-02-02 Gregory Aharonian Use of coca leaf or Valerian root to reduce bitterness in foods containing unsweetened cocoa
IT201700056408A1 (it) * 2017-05-24 2018-11-24 Inpha Duemila Srl Composizione orale per il controllo dell’iperlipidemia e dei fattori di rischio cardio-vascolare.

Also Published As

Publication number Publication date
WO2020208404A1 (fr) 2020-10-15

Similar Documents

Publication Publication Date Title
Xie et al. Phytic acid enhances the oral absorption of isorhamnetin, quercetin, and kaempferol in total flavones of Hippophae rhamnoides L.
EP2709607A1 (fr) Composition hydrosoluble comprenant de la curcumine ayant une plus grande biodisponibilité et procédé associé
AU2019213699B2 (en) Compositions comprising berberine
CN1278171A (zh) 作为酰基CoA－胆固醇－O－酰基转移酶抑制剂、巨噬细胞－脂质复合物在动脉壁上累积的抑制剂以及肝病的预防或治疗剂的柚苷或柚苷配基
JP4261337B2 (ja) リパーゼ阻害剤とショ糖脂肪酸エステルとを含む医薬組成物
EP3429568A1 (fr) Composition pharmaceutique utilisée pour le traitement thérapeutique du cancer et ses complications
US20200268770A1 (en) Pharmaceutical composition used for treating metabolic syndrome disorders, infectious diseases, and complications thereof
WO2020208404A1 (fr) Composition de poudre hautement disponible contenant du riz rouge
KR100625399B1 (ko) 리파아제 억제제 및 글루코마난을 포함하는 약학 조성물
CN1278170A (zh) 作为酰基CoA－胆固醇－O－酰基转移酶抑制剂、巨噬细胞－脂质复合物在动脉壁上累积的抑制剂以及肝病的预防或治疗剂的橙皮苷或橙皮素
RS20060437A (sr) Farmaceutski sastavi koji sadrže više primarne alkohole i ezetimib i postupak za njihovo dobijanje
US20210060034A1 (en) The Pharmaceutical Composition Intended to Inhibit HIV Infectivity in Order to Treat the Acquired Immune Deficiency Syndrome (AIDS) and Its Complications
WO2023037254A1 (fr) Méthodes et composés pour le traitement d'infections par un virus de la famille des coronaviridae
US20230181485A1 (en) Uses and Formulations of Cannabinoids
EP2658536B1 (fr) Gemcabène et dérivés pour le traitement de la pancréatite
WO2014173957A2 (fr) Composé
TWI817867B (zh) 1,2,3,4-四氫喹啉類化合物用於改善動脈粥狀硬化的用途
CN112076187B (zh) 安卓锭在制备用于预防或治疗非酒精性脂肪肝的药物中的用途
WO2007122636A1 (fr) Compositions pharmaceutiques contenant des acides gras à chaîne longue, et leur procédé de production
US20240101593A1 (en) Ursolic acid preparations and uses thereof
AU2022316441A1 (en) Combination for use for the treatment of hypercholesterolemia, hyperlipidemia, cardiovascular disease and metabolic syndrome
WO2023009976A1 (fr) Formulations thérapeutiques issues de pelargonium sp. et méthodes d'utilisation contre des infections virales respiratoires
FR2970178A1 (fr) Promedicaments pour une delivrance specifique au niveau du foie et une meilleure tolerance
HK1238159A1 (en) Gemcaben for treating pancreatitis
KR20100137674A (ko) 리나룰을 유효성분으로 함유하는 콜레스테롤 저하용 조성물

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211006

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)